Table 2. Network comparison of prognostic and response outcomes of different therapies for biliary tract cancer treatments.
| 1-OS | BSC | 0.99(0.61,1.59) | 0.47(0.27,0.82) | 0.63(0.32,1.23) | 0.65(0.39,1.07) | 0.40(0.24,0.67) | 0.37(0.21,0.64) | 2-OS | |
| 0.85(0.63,1.14) | FU | 0.48(0.29,0.77) | 0.63(0.35,1.14) | 0.65(0.45,0.95) | 0.41(0.26,0.62) | 0.37(0.23,0.60) | |||
| 0.34(0.20,0.58) | 0.40(0.23,0.69) | FU+PLA | 1.33(0.76,2.32) | 1.37(0.98,1.92) | 0.85(0.68,1.07) | 0.78(0.56,1.08) | |||
| 0.58(0.39,0.85) | 0.68(0.43,1.07) | 1.72(0.96,3.07) | GEM | 0.97(0.62,1.51) | 0.62(0.49,0.79) | 0.57(0.40,0.80) | |||
| 0.54(0.36,0.82) | 0.64(0.42,0.97) | 1.62(1.07,2.44) | 0.94(0.60,1.47) | GEM+FU | 1.56(0.94,2.60) | 0.91(0.72,1.16) | |||
| 0.29(0.18,0.46) | 0.34(0.21,0.54) | 0.85(0.65,1.12) | 0.50(0.30,0.83) | 0.53(0.39,0.72) | GEM+PLA | 1.71(0.98,3.00) | |||
| 0.25(0.14,0.44) | 0.30(0.17,0.53) | 0.75(0.50,1.13) | 0.44(0.24,0.79) | 0.46(0.30,0.72) | 0.88(0.65,1.20) | GEM+PLA+TAR | |||
| 1-PFS | BSC | 0.73(0.39,1.37) | 0.43(0.18,1.04) | - | 0.64(0.28,1.48) | 0.38(0.18,0.82) | 0.33(0.14,0.75) | - | 2-PFS |
| 0.80(0.51,1.27) | FU | 0.59(0.20,1.74) | - | 0.88(0.31,2.51) | 0.52(0.19,1.41) | 0.45(0.16,1.27) | - | ||
| 0.30(0.18,0.51) | 0.37(0.26,0.53) | FU+PLA | - | 1.49(0.88,2.54) | 0.88(0.58,1.34) | 0.76(0.45,1.27) | - | ||
| 0.54(0.29,1.02) | 0.68(0.42,1.09) | 1.82(1.14,2.92) | GEM | - | - | - | - | ||
| 0.46(0.28,0.74) | 0.57(0.44,0.73) | 1.53(1.19,1.96) | 0.84(0.56,1.25) | GEM+FU | 0.59(0.43,0.82) | 0.51(0.33,0.79) | - | ||
| 0.30(0.18,0.48) | 0.37(0.28,0.49) | 0.99(0.80,1.22) | 0.54(0.36,0.83) | 0.65(0.56,0.75) | GEM+PLA | 0.86(0.64,1.16) | - | ||
| 0.24(0.14,0.40) | 0.30(0.21,0.42) | 0.80(0.61,1.05) | 0.44(0.28,0.69) | 0.53(0.42,0.66) | 0.81(0.68,0.96) | GEM+PLA+TAR | |||
| 0.61(0.30,1.26) | 0.77(0.42,1.38) | 2.05(1.14,3.70) | 1.13(0.79,1.61) | 1.35(0.79,2.29) | 2.07(1.19,3.60) | 2.56(1.44,4.57) | GEM+TAR | ||
| ORR | BSC | 0.32(0.08,1.17) | 1.09(0.28,4.53) | 2.61(0.57,12.18) | 1.13(0.34,3.82) | 1.90(0.53,7.32) | 0.98(0.12,7.54) | 1.45(0.24,8.94) | DCR |
| 4.39(0.57,56.26) | FU | 3.42(0.68,18.73) | 8.00(2.08,35.52) | 3.56(0.76,16.12) | 5.93(1.23,29.96) | 3.00(0.43,22.20) | 4.44(0.84,25.79) | ||
| 27.66(3.25,572.49) | 6.36(0.59,94.63) | FU+PLA | 2.39(0.53,10.49) | 1.03(0.53,1.82) | 1.73(0.78,3.71) | 0.90(0.11,6.36) | 1.34(0.22,7.69) | ||
| 14.88(1.73,214.86) | 3.39(1.14,11.02) | 0.54(0.04,5.10) | GEM+FU | 0.43(0.11,1.67) | 0.73(0.17,3.06) | 0.37(0.09,1.45) | 0.55(0.21,1.45) | ||
| 20.29(2.64,361.41) | 4.66(0.49,57.97) | 0.74(0.29,1.58) | 1.35(0.16,15.49) | GEM+PLA | 1.68(1.07,2.80) | 0.87(0.12,5.81) | 1.30(0.25,6.96) | ||
| 40.85(4.85,780.55) | 9.39(0.91,126.47) | 1.49(0.48,3.94) | 2.72(0.30,34.12) | 1.99(1.08,3.78) | GEM+PLA+TAR | 0.51(0.07,3.56) | 0.77(0.14,4.31) | ||
| 10.70(0.64,252.14) | 2.39(0.31,19.89) | 0.37(0.02,6.75) | 0.71(0.12,4.01) | 0.51(0.03,8.41) | 0.25(0.01,4.53) | GEM+TAR | 1.51(0.56,4.06) | ||
| 7.24(0.59,129.02) | 1.62(0.30,8.85) | 0.26(0.01,3.32) | 0.48(0.13,1.62) | 0.35(0.02,4.06) | 0.18(0.01,2.18) | 0.67(0.20,2.23) | GEM |
Abbreviation: BSC, best supportive care; GEM, gemcitabine; OXA, Oxaliplatin; CIS, Cisplatin; PLA, Platinum; FU, fluorouracil; TAR, targeted drugs; OS, overall survival; PFS, progression free survival; ORR, overall response rate; DCR, disease control rate. The data is in the form of hazard ratio (HR) and corresponding 95% credible intervals (CrI) for 1-OS, 2-OS, 1-PFS and 2-PFS and in the form of odds ratio (OR) and corresponding 95% CrI for ORR and DCR.